Brief: Tiziana Announces Submission Of Amendment To Investigational New Drug Application To Advance Oral Foralumab
04/02/2022 12:02
Feb 4 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES SUBMISSION OF AMENDMENT TO
INVESTIGATIONAL NEW
DRUG APPLICATION TO ADVANCE ORAL FORALUMAB, A FULLY HUMAN
ANTI-CD3 MONOCLONAL ANTIBODY, IN PATIENTS WITH CROHN’S DISEASE
* TIZIANA LIFE SCIENCES LTD - AWAITING FDA'S COMMENTS ON
AMENDED
TILS-014 PROTOCOL AND, WITH CLEARANCE OF AMENDMENT
* TIZIANA LIFE SCIENCES LTD - ANTICIPATES COMPLETING PHASE
1B
STUDY BY Q4 OF 2022
Source text for Eikon: ID:nGNX1MGT1p
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis